Extensive skeletal muscle uptake of 18F-FDG: Relation to immunosuppressants?

Journal of Nuclear Medicine Technology

Volumn 32, Issue 4, 2004, Pages 206-208

  Groves, Ashley M ^a   Cheow, Heok K ^a   Win, Thida ^b   Balan, Kottekkattu K ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

18F FDG; Immunosuppressants; Muscle uptake; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMMUNOSUPPRESSIVE AGENT; LANSOPRAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; TACROLIMUS; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MYCOPHENOLIC ACID; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEART TRANSPLANTATION; HUMAN; LUNG BIOPSY; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; SKELETAL MUSCLE; B CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; DRUG INTERACTION; FEVER; HEART LUNG TRANSPLANTATION; METABOLISM; METHODOLOGY; SCINTISCANNING; THORAX RADIOGRAPHY;

ADULT; DIAGNOSIS, DIFFERENTIAL; DRUG INTERACTIONS; FEMALE; FEVER; FLUORODEOXYGLUCOSE F18; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; MUSCLE, SKELETAL; MYCOPHENOLIC ACID; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHY, THORACIC; RADIOPHARMACEUTICALS; TACROLIMUS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 28744455629     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641-1674.
2. Shreve PD, Ansai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
3. Engel H, Steinert H, Buck A, et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulation. J Nucl Med. 1996;37:441-446.
4. Bar-Shalom R. Muscle uptake of 18-fluorine fluorodeoxyglucose. Semin Nucl Med. 2000;4:306-309.
5. Yasuda S, Ide M, Takagi S, et al. Elevated F-18 FDG in skeletal muscle. Clin Nucl Med. 1998;23:111-112.
6. Yasuda S, Fuji H, Takahashi W, et al. Elevated F-18 uptake in psoas muscle. Clin Nucl Med. 1998;23:717-718.
7. Lin E, Bhola R. Unilateral diaphragmatic crus uptake on FDG positron emission tomographic imaging. Clin Nucl Med. 2001;26:479.
8. Barrington SF, Maisey MN. Skeletal uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med. 1996;37:1127-1129.
9. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002;29;1393-1398.
10. 18F-FDG PET/CT. J Nucl Med. 2003;44:170-176.
11. 18F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging. 2002;29:648-654.
12. Mehta DK, ed. British National Formulary. 44th ed. London, U.K.: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2002:431.